Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Sotera Health reported Q3 2026 net revenues of $324.9 million, up 4.4% year-over-year on both as-reported and constant currency bases, with net income of $58 million ($0.20 diluted EPS). Adjusted EPS rose 12% to $0.29, and Adjusted EBITDA margin expanded nearly 100 basis points sequentially to 52.5%. Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency, while Nordion fell 11.5% on expected Co-60 harvest timing. The company reaffirmed its FY2026 outlook of $1.233B-$1.250B revenue and $632M-$641M Adjusted EBITDA, and net leverage improved to 2.9x, within its 2.0x-3.0x target.
Key figures
- Eps
- 0.2
- Revenue
- 324886000
- Guidance
- FY2026 net revenues $1.233B-$1.250B (5.25%-6.75% constant currency growth); Adjusted EBITDA $632M-$641M (5.75%-7.25% constant currency growth); Adjusted EPS $0.95-$1.01
- Revenue Yoy
- 4.4%
- Cash
- 412393000
- Net income
- 58391000
- Total debt
- 2244260000
- Adjusted eps
- 0.29
- Adjusted ebitda
- 170665000
- Adjusted eps yoy
- 12%
- Net leverage ratio
- 2.9x
- Nordion revenue q3
- 55024000
- Adjusted ebitda growth
- 3.9%
- Adjusted ebitda margin
- 52.5%
- Nelson labs revenue q3
- 60557000
- Operating cash flow q3
- 111000000
- Sterigenics revenue q3
- 209305000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.